Immunomodulators for immunocompromised patients hospitalized for COVID-19: a meta-analysis of randomized controlled trials

Ilias Ι. Siempos(Brigham and Women's Hospital), Lauren Demerville(Hôpital Saint-Louis), Muriel Fartoukh(Université Paris-Est Créteil), Eleni Papoutsi(National and Kapodistrian University of Athens), Matthieu Resche‐Rigon(Inserm), Gabriel Baron(Délégation Paris 5), Annick Tibi(Assistance Publique – Hôpitaux de Paris), Joseph Emmerich(Délégation Paris 5), Matthieu Mahévas(Délégation Paris 5), Cécile Kedzia(Collaborative Group (United States)), Viviane Cordeiro Veiga(St John of God Subiaco Hospital), Frédéric Pène(Centre National de la Recherche Scientifique), Nikoleta A. Xixi(National and Kapodistrian University of Athens), Philippe Ravaud(Inserm), Xavier Mariette(Inserm), Drifa Belhadi(Inserm), Westyn Branch‐Elliman(VA Greater Los Angeles Healthcare System), Damien Vanhoye(Collaborative Group (United States)), Olivier Hermine(Centre National de la Recherche Scientifique), Raphaël Porcher(Hotel Dieu Hospital), F. Schlemmer(Collaborative Group (United States)), André C. Kalil(Nebraska Medical Center), Karine Lacombe(Inserm), Αναστασία Κοτανίδου(National and Kapodistrian University of Athens), Serge Bureau(Collaborative Group (United States)), Élie Azoulay(Hôpital Saint-Louis), Élodie Perrodeau(Collaborative Group (United States)), Marc Humbert(Inserm), Pierre‐Louis Tharaux(Inserm), Konstantinos Gkirgkiris(National and Kapodistrian University of Athens), Maxime Dougados(Inserm), Yazdan Yazdanpanah(Inserm), Bertrand Guidet(Sorbonne Université), Valérie Pourchet-Martinez(Collaborative Group (United States)), Jacques Cadranel(Sorbonne Université), Alexandre Biasi Cavalcanti(Université de Tours)
EClinicalMedicine
February 8, 2024
Cited by 8


Related Papers